LLS Community wants to celebrate your amazing survivor stories! Complete the My Story section of your profile to share a brief review of your cancer journey, information about your diagnosis and treatment/clinical trials participation, tips and resources that have helped you, and/or your photo (if you would like). Instructions at https://www.lls.org/article/telling-my-story-on-lls-community.
Ronald Levy, professor of medicine and former chief of the Division of Oncology at Stanford University School of Medicine, helped develop and test the first US Food and Drug Administration (FDA)-approved monoclonal antibody against cancer for the treatment of B-cell lymphoma. Rituximab is now a standard of treatment alone and also in combination with chemotherapy regimens. Levy is receiving LLS funding through the Translational Research Program for research into an immunotransplant...
Speaking from the heart, Vice President Joseph Biden addressed thousands of cancer researchers today in a packed hall at the American Society of Clinical Oncology (#ASCO16) annual meeting in Chicago, to tout his Cancer Moonshot initiative. The theme of this year’s #ASCO16 meeting, “Collective Wisdom – The Future of Patient-Centered Care and Research,” is perfectly aligned with the goals of the Moonshot, Biden told the rapt audience.
The American Society of Clinical Oncology (#ASCO16) annual meeting featured several significant oral scientific presentations on the blood cancers over the weekend here in Chicago. CPX-351: A session on hematological malignancies Saturday afternoon included a discussion of final data from the Phase 3 clinical trial of Celator’s drug CPX-351 (Vyxeos ®). LLS invested substantially in this study through our Therapy Acceleration Program (TAP). The study was in a small subset of elderly pati...
The American Society of Clinical Oncology (#ASCO16) annual meeting kicked off today as more than 30,000 researchers from around the world converged in Chicago to share their latest clinical findings on treatments and diagnostics for all cancers, and to exchange ideas about how to improve outcomes for cancer patients. Putting patients at the center of cancer care and research is this year’s theme at ASCO, something we at The Leukemia & Lymphoma Society (LLS) try to do every day. Sprin...
Helen Heslop, M.D., leads a team of scientists being funded through LLS’s Specialized Center of Research Program (SCOR). The project brings together researchers from different institutions to test a half dozen novel approaches to cancer immunotherapy – all of which harness the patient's own immune system to fight the cancer. Heslop, a professor in the Department of Medicine and Pediatrics at Baylor College of Medicine and the director of the Center for Cell and Gene Therapy, pioneered...
The Food & Drug Administration’s accelerated approval of an immunotherapy for patients with Hodgkin lymphoma who have failed other treatments is a positive development for patients who face a very poor prognosis. While Hodgkin lymphoma is now considered one of the most curable forms of cancer – with a more than 86 percent five-year-survival rate overall – those patients who relapse after treatment have a much reduced chance of survival. FDA’s approval of nivolumab (Opdivo®)...
What is AML? What research is underway? And what resources are available to patients? The Leukemia & Lymphoma Society recently joined up with Patient Power and the MDS Alliance to host an AML Awareness Day and answer those questions. The April 21 webcast was moderated by Carol Preston, host of Patient Power, an online portal offering cancer information for both patients and professionals. Preston is also a chronic lymphocytic leukemia (CLL) survivor. The panelists were Ellen Ritc...
Wanting to make sure the patient voice is heard when it comes to the development of new therapies, The Leukemia & Lymphoma Society (LLS) recently brought a delegation to Washington D.C. to share personal experiences with the U.S. Food & Drug Administration (FDA). Plans for a research study to learn what patients and caregivers are looking for in new treatments were also presented. LLS’s Office of Public Policy knows the importance of pushing for new drug development, but you can...
Ibrutinib just became the latest therapy for blood cancers to receive an expanded approval use by the U.S. Food and Drug Administration. Such therapeutic advances have been making great progress in recent months and a number of investigational agents – first approved for one disease and population – are being expanded to new uses. Almost 300 drugs for blood cancers are currently in clinical trials or awaiting FDA review.
The Leukemia & Lymphoma Society recently brought together a world-renowned panel of thought leaders to discuss the latest advances and insights into blood cancer research and treatment, drug costs and patient access, and patient advocacy and policy. “There’s never a good time to get cancer but this is a phenomenal time to be fighting it,” said Louis J. DeGennaro, president and CEO of The Leukemia & Lymphoma Society (LLS).
